A jury voted in favor of Amgen ( AMGN) Tuesday in a patent dispute case, according to a Bloomberg report.

The ruling determines in effect that Roche may not sell Mircera, its rival medicine to Amgen's Aranesp and Epogen anemia drugs, in the U.S.

Amgen shares were rising 87 cents, or 1.6%, to $56.99 in recent trading.

If you liked this article you might like

Stocks Mixed After Working on Railroad

Stocks Mixed After Working on Railroad

Stocks Log a Volatile Win

Stocks Log a Volatile Win

Stocks Get Spooked

Stocks Get Spooked

Dow's Gain: 199.89 as GDP Wows Wall Street

Dow's Gain: 199.89 as GDP Wows Wall Street

Stocks Trip Over Charts; Nasdaq Pummeled

Stocks Trip Over Charts; Nasdaq Pummeled